$1.20
5.16% today
Nasdaq, Apr 01, 06:36 pm CET
ISIN
US10501E2019
Symbol
BCLI

Brainstorm Cell Therapeutics Inc. Stock price

$1.26
-0.34 21.25% 1M
-2.19 63.53% 6M
-1.01 44.49% YTD
-9.84 88.65% 1Y
-49.14 97.50% 3Y
-68.34 98.19% 5Y
-65.49 98.11% 10Y
Nasdaq, Closing price Mon, Mar 31 2025
+0.07 5.88%
ISIN
US10501E2019
Symbol
BCLI
Sector

Key metrics

Market capitalization $7.19m
Enterprise Value $7.86m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-13.31m
Cash position $170.00k
EPS (TTM) EPS $-3.49
P/E forward negative
Short interest 2.27%
Show more

Is Brainstorm Cell Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,804 stocks worldwide.

Brainstorm Cell Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Brainstorm Cell Therapeutics Inc.:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Brainstorm Cell Therapeutics Inc.:

Buy
100%

Financial data from Brainstorm Cell Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.25 0.25
7% 7%
-
-0.25 -0.25
7% 7%
-
- Selling and Administrative Expenses 8.43 8.43
14% 14%
-
- Research and Development Expense 4.37 4.37
61% 61%
-
-13 -13
39% 39%
-
- Depreciation and Amortization 0.25 0.25
7% 7%
-
EBIT (Operating Income) EBIT -13 -13
38% 38%
-
Net Profit -14 -14
14% 14%
-

In millions USD.

Don't miss a Thing! We will send you all news about Brainstorm Cell Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Brainstorm Cell Therapeutics Inc. Stock News

Neutral
Seeking Alpha
one day ago
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI ) Q4 2024 Earnings Conference Call March 31, 2025 8:30 AM ET Company Participants Michael Wood - Investor Relations Chaim Lebovits - President & Chief Executive Officer Alla Patlis - Interim Chief Financial Officer Bob Dagher - Executive Vice President & Chief Medical Officer Haro Hartounian - Executive Vice President & Chief Operating Officer Conf...
Neutral
PRNewsWire
one day ago
Conference call and webcast at 8:30 a.m. Eastern Time today NEW YORK , March 31, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the fiscal year ended December 31, 2024, and provided a corporate update.
Neutral
PRNewsWire
6 days ago
NEW YORK , March 26, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading biotechnology company committed to the development and commercialization of best-in-class autologous cellular therapies for the treatment of neurodegenerative diseases, today announced that it has been granted the exact compliance extension it requested from the Nasdaq Hearings Panel through Ju...
More Brainstorm Cell Therapeutics Inc. News

Company Profile

Brainstorm Cell Therapeutics, Inc. operates as a biotechnology company, which develops and commercializes adult stem cell therapeutic products. It focuses on utilizing the patients own bone marrow stem cells to generate neuron-like cells that may provide an effective treatment initially for amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis and spinal cord injury. The company was founded on September 22, 2000 and is headquartered in New York, NJ.

Head office United States
CEO Chaim Lebovits
Employees 29
Founded 2000
Website www.brainstorm-cell.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today